Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ493MR)

This product GTTS-WQ493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12273MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ9722MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ7060MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ4332MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ14062MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ9647MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ3013MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ7657MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW